How to Get Rezdiffra (Resmetirom) in Michigan

What Is Rezdiffra and Why Does It Matter for Michigan Patients?

Rezdiffra (resmetirom) is the first drug approved by the FDA specifically for MASH with moderate-to-advanced hepatic fibrosis (stages F2 and F3). It is a selective thyroid hormone receptor beta (THR-beta) agonist that targets liver fat metabolism without producing systemic thyroid effects at therapeutic doses. The FDA granted accelerated approval on March 14, 2024, based on the MAESTRO-NASH trial.

Michigan carries a significant MASH burden. Approximately 5% of U.S. adults have MASH, according to NHANES-based prevalence estimates published by the NIH, and Michigan's rates of obesity and type 2 diabetes track above the national median per CDC BRFSS surveillance data. Before resmetirom, no pharmacotherapy existed for MASH outside of off-label vitamin E and pioglitazone. That gap left Michigan hepatologists with lifestyle counseling as the sole first-line option for fibrosis regression.

In the MAESTRO-NASH phase 3 trial (N=966), resmetirom 80 mg and 100 mg produced MASH resolution without worsening fibrosis in 25.9% and 29.9% of patients, respectively, compared with 9.7% for placebo at 52 weeks [1]. Fibrosis improvement by at least one stage occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% for placebo [1]. These numbers represent the first time any drug demonstrated histological fibrosis improvement in a registration-grade MASH trial.

Step-by-Step: Getting a Rezdiffra Prescription in Michigan

The prescription process follows a predictable sequence. Here is what Michigan patients should expect from first appointment through medication in hand.

1. Identify a qualified prescriber. Any Michigan-licensed physician (MD or DO), nurse practitioner, or physician assistant with prescriptive authority can write a Rezdiffra prescription. Hepatologists and gastroenterologists are the most common prescribers because MASH diagnosis and staging sit within their scope. The AASLD practice guidance on MASLD recommends specialist evaluation for patients with fibrosis stage F2 or higher.

2. Complete baseline labs and fibrosis staging. Before prescribing, your provider will order a liver panel (ALT, AST, bilirubin, albumin, INR), complete blood count, thyroid function tests (TSH, free T4), and a fasting lipid panel. Fibrosis must be confirmed at stage F2 or F3. Most Michigan practices use vibration-controlled transient elastography (FibroScan) as the non-invasive standard. A liver stiffness measurement of 8.0 to 13.9 kPa generally corresponds to F2-F3 per Baveno VII consensus thresholds. Liver biopsy remains the reference standard but is not required if non-invasive testing is concordant.

3. Confirm the diagnosis is MASH, not simple steatosis. The FDA prescribing label for Rezdiffra specifies the indication as noncirrhotic MASH with moderate-to-advanced fibrosis. Patients with decompensated cirrhosis (Child-Pugh B or C) or simple fatty liver without fibrosis fall outside the approved indication.

4. Submit prior authorization. Nearly every Michigan commercial plan and Michigan Medicaid require prior authorization for Rezdiffra. Your prescriber's office will handle the submission. This process takes 5 to 15 business days in most cases.

5. Fill at a specialty or 503A pharmacy. Once approved, the prescription routes to a specialty pharmacy or a Michigan-licensed 503A compounding pharmacy. Patients typically receive the medication within 3 to 7 business days after PA clearance.

Telehealth Access to Rezdiffra in Michigan

Michigan law permits telehealth prescribing of Rezdiffra. This is a real option. The Michigan Public Health Code and LARA telehealth guidance allow prescribers to establish a patient-provider relationship via synchronous audio-video visit for non-controlled substances. Resmetirom is not a controlled substance, so it qualifies.

Telehealth consultations for Rezdiffra follow the same clinical protocol as in-person visits. The prescriber still needs baseline labs and fibrosis staging results, but the patient can complete blood draws at any Michigan lab (Quest, Labcorp, or hospital-affiliated draw sites) and obtain a FibroScan at a local imaging center or gastroenterology office. Results upload to the telehealth provider electronically.

Several national MASH-focused telehealth platforms now serve Michigan, and HealthRX connects patients with providers experienced in prescribing thyroid hormone receptor agonists for liver disease. The practical advantage for Michigan patients outside metro Detroit or Grand Rapids is significant: MASH specialists are concentrated in academic centers like Michigan Medicine (Ann Arbor) and Henry Ford Health (Detroit), so telehealth removes the 2-to-4-hour drive for patients in the Upper Peninsula, northern Lower Michigan, or rural western counties.

A telehealth prescriber licensed in Michigan carries the same prescriptive authority as one seen in person. No additional paperwork or in-person follow-up is required by state law for ongoing Rezdiffra management, though most providers schedule follow-up labs at 12 and 24 weeks per the monitoring schedule in the Rezdiffra prescribing information.

Michigan Medicaid and Commercial Insurance Coverage

Michigan Medicaid covers Rezdiffra with prior authorization. The PA process requires documentation of MASH diagnosis with fibrosis stage F2 or F3, failure or contraindication to lifestyle intervention (typically 6 months of documented diet and exercise counseling), and baseline liver and thyroid labs. The Michigan Department of Health and Human Services Pharmacy Benefits formulary classifies it as a specialty tier agent.

For commercial plans (Blue Cross Blue Shield of Michigan, Priority Health, HAP, McLaren), coverage decisions follow the insurer's medical policy. BCBSM, the state's largest commercial carrier, published a medical policy for resmetirom in late 2024 that requires biopsy-confirmed or non-invasive-confirmed F2-F3 fibrosis and documentation of MASH etiology (ruling out alcohol-associated liver disease, viral hepatitis, and autoimmune causes).

The list price of Rezdiffra is approximately $47,400 per year. Madrigal Pharmaceuticals offers a copay assistance program that reduces out-of-pocket costs for commercially insured patients. Michigan Medicaid patients are not eligible for manufacturer copay cards per federal anti-kickback statute rules, but their cost-sharing is governed by Medicaid fee schedules and is typically minimal.

A 2024 cost-effectiveness analysis published in Hepatology estimated resmetirom's incremental cost-effectiveness ratio (ICER) at $52,000 to $87,000 per quality-adjusted life year, depending on assumptions about fibrosis progression. That range falls below the conventional $100,000-per-QALY willingness-to-pay threshold used by most U.S. payers, which supports the clinical and economic case for coverage.

Prior Authorization: What Michigan Prescribers Need to Submit

Prior authorization is the single biggest bottleneck in the Michigan Rezdiffra access pathway. Here is what the submission requires, distilled from Michigan Medicaid PA criteria and the most common commercial plan requirements:

Clinical documentation checklist:

• Confirmed MASH diagnosis (ICD-10 code K75.81)
• Fibrosis stage F2 or F3 confirmed by liver biopsy (METAVIR or NAS scoring) or non-invasive test (FibroScan with liver stiffness 8.0-13.9 kPa, or FIB-4 score with concordant imaging)
• Exclusion of other chronic liver disease etiologies (hepatitis B/C serology negative, ANA/ASMA for autoimmune hepatitis, iron studies, ceruloplasmin if age-appropriate)
• Baseline TSH within normal limits
• Baseline ALT and AST values
• Documentation of at least 6 months of lifestyle modification (diet, exercise, weight management counseling)
• Prescriber attestation that the patient does not have decompensated cirrhosis

Michigan Medicaid decisions typically arrive within 10 business days. Commercial plans vary: BCBSM averages 7 to 10 business days, while Priority Health and HAP may take up to 15. If denied, Michigan patients have appeal rights under both Medicaid fair hearing rules and commercial plan grievance procedures. The AASLD's MASH practice guidance and the MAESTRO-NASH trial data [1] serve as strong supporting evidence for appeals.

503A Compounding Pharmacies and Specialty Pharmacy Options in Michigan

Rezdiffra is manufactured by Madrigal Pharmaceuticals as a branded tablet (60 mg and 100 mg strengths). Most Michigan patients will fill their prescription through a specialty pharmacy. Accredo, CVS Specialty, and Optum Specialty are the three largest specialty pharmacy networks serving Michigan, and all carry Rezdiffra.

Michigan-licensed 503A compounding pharmacies are authorized to compound and dispense medications under a patient-specific prescription per Michigan Board of Pharmacy regulations. However, resmetirom compounding from bulk substance is currently limited because the drug is under patent protection and commercially available. 503A pharmacies in Michigan may fill the branded product when contracted with the patient's insurer or when acting as a dispensing pharmacy.

For patients in rural Michigan, mail-order specialty pharmacy is the standard fulfillment model. Specialty pharmacies ship temperature-controlled packages via overnight carriers. Rezdiffra does not require refrigeration (store at 68 to 77 degrees Fahrenheit), so shipping logistics are straightforward compared to injectable biologics.

Labs and Monitoring While on Rezdiffra in Michigan

The Rezdiffra prescribing information specifies a defined monitoring schedule. Michigan providers should order these labs before initiation and during treatment:

Before starting:

• Hepatic panel (ALT, AST, total bilirubin, alkaline phosphatase, albumin)
• TSH and free T4
• Fasting lipid panel (resmetirom lowers LDL-C by approximately 14% as a secondary pharmacologic effect per MAESTRO-NASH data [1])
• CBC with differential
• FibroScan or equivalent fibrosis assessment

During treatment:

• Hepatic panel at weeks 12 and 24, then every 6 months
• TSH at week 12, then annually (to detect rare hypothalamic-pituitary axis suppression)
• Lipid panel at week 12 to assess LDL-C response
• FibroScan at 12 months to assess fibrosis trajectory

Michigan's lab infrastructure supports this schedule well. Quest Diagnostics operates 47 patient service centers across the state, and Labcorp has 32. Hospital-affiliated labs at Beaumont, Spectrum Health, and Michigan Medicine accept outpatient orders from telehealth providers.

The MAESTRO-NASH trial reported the most common adverse events as diarrhea (27.0% for 100 mg vs. 16.8% placebo) and nausea (22.2% vs. 13.5%) [1]. These gastrointestinal effects were typically mild, self-limited, and concentrated in the first 4 to 8 weeks of treatment. Michigan prescribers should counsel patients to take resmetirom with food, which reduces GI symptoms per the label instructions.

Who Can Prescribe Rezdiffra in Michigan: MD, NP, and PA Scope

Michigan's prescribing laws define three categories of professionals authorized to prescribe Rezdiffra.

Physicians (MD/DO): Full, unrestricted prescriptive authority. Hepatologists, gastroenterologists, endocrinologists, and primary care physicians all prescribe Rezdiffra in Michigan. No specialty restriction applies.

Nurse Practitioners (NP): Michigan granted NPs full practice authority effective December 2024 under Public Act 187 of 2024. NPs with prescriptive authority can independently prescribe Rezdiffra without physician oversight, though collaborative agreements were required before this legislation took effect.

Physician Assistants (PA): PAs in Michigan prescribe under a practice agreement with a supervising physician. A PA working in a gastroenterology or hepatology practice can prescribe Rezdiffra as part of their delegated authority. The Michigan Board of Medicine PA rules require the practice agreement to specify the PA's prescribing scope.

All three provider types can submit prior authorization requests, order the required baseline labs, and manage ongoing monitoring. The practical difference is access: in underserved areas of Michigan, NPs and PAs may be the only local prescribers, making their authority particularly relevant for MASH patients who otherwise would need to travel to a specialist center.

Transferring a Rezdiffra Prescription to Michigan

Patients moving to Michigan or traveling from another state can transfer an existing Rezdiffra prescription. Michigan Board of Pharmacy rules permit prescription transfers between states for non-controlled substances. The process requires the receiving Michigan pharmacy to contact the originating out-of-state pharmacy to verify and transfer the prescription record.

One practical consideration: prior authorization does not transfer between insurers. If a patient switches from an out-of-state plan to a Michigan-based plan (or to Michigan Medicaid), a new PA submission is required. The patient's existing medical records, lab results, and fibrosis staging carry over and can be used to support the new PA request, which typically shortens the approval timeline to 5 to 7 business days.

For patients who filled Rezdiffra through an out-of-state specialty pharmacy, the new Michigan specialty pharmacy will need to re-enroll the patient in the specialty pharmacy's intake process. This takes 1 to 3 business days. Patients should plan for a 2-week overlap supply when relocating to avoid treatment gaps.